Renalytix AI upbeat on latest 'KidneyIntelX' research

Artificial intelligence (AI)-focussed diagnostics company Renalytix AI revealed more details of results from a multi-centre clinical validation of ‘KidneyIntelX’ on Wednesday, which reportedly demonstrated that KidneyIntelX could identify patients at the highest risk of early-stage diabetic kidney disease, with more accuracy than existing care methods.

The AIM-traded firm said KidneyIntelX achieved a 62% positive predictive value (PPV) in the top 16% of the population, compared to a PPV of 41% for the existing standard of care.

It said the data would be presented at the American Diabetes Association’s annual conference, and submitted to the Food and Drug Administration (FDA) under its ‘Breakthrough Device’ designation.

The board said the study was further validation to support the ongoing commercialisation of KidneyIntelX, targeting more than 12 million Americans with diabetic kidney disease, and highlighted the need for better risk stratification tools to improve patient outcomes.

“This data supports the ongoing commercialisation of KidneyIntelX, targeting more than 12 million Americans with diabetic kidney disease,” the board said in its statement.

“While only 20% of patients with diabetic kidney disease will experience progression over a five-year period, diabetic kidney disease accounts for nearly half of all cases of end-stage kidney disease.

“While studies have shown that nephrology care can slow the progression of chronic and diabetic kidney diseases, as well as reduce costs, it is impossible for nephrologists to see all patients with stage one to three diabetic kidney disease, [and] therefore better risk stratification tools are needed to facilitate referrals for the appropriate patients.”

At 0840 BST, shares in Renalytix AI were up 2.13% at 454.5p.